StockData

Outlook Therapeutics vs Scinai Immunotherapeutics

OTLK and SCNI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OTLK and SCNI compare

Scinai Immunotherapeutics scores higher on the StockData Score (6 against 4 for Outlook Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOTLKSCNI
Size and price
Market cap$87.8M–
Share price$0.361$0.372
Change, 1 year−77.0%−96.2%
Change, 5 years−98.7%−100.0%
Beta (5Y)3.721.20
Employees1745
StockData Score
Total score46 (better)
Valuation score00
Growth score01 (better)
Performance score00
Health score45 (better)
Dividend score00
Growth
Revenue growth (TTM)–99.2%
Net income growth (TTM)–−273%
Profitability
Gross margin–−202%
Operating margin–−575%
Net margin–−634%
FCF margin–−462%
Return on equity–−84.8%
Return on invested capital–−74.7%
Financial health
Debt / equity–0.00
Current ratio0.811.56 (better)
Altman Z-score−40.77–
Piotroski F-score13 (better)
Dividends and buybacks
Buyback yield−62.3%–
Shareholder yield−62.3%–
Ownership
Held by institutions8.4%–
Held by insiders28.5%7.4%
Insider net buying, 12 months$7.9M–
Short interest, % of float20.4%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.